Arcturus Therapeutics Holdings Stock Z Score
ARCT Stock | USD 33.77 0.91 2.77% |
Arcturus | Z Score |
Arcturus Z Score Analysis
Arcturus Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Arcturus Therapeutics Z Score | 18.06 |
Most of Arcturus Therapeutics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcturus Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
Arcturus Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcturus Therapeutics is extremely important. It helps to project a fair market value of Arcturus Stock properly, considering its historical fundamentals such as Z Score. Since Arcturus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcturus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcturus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
In accordance with the company's disclosures, Arcturus Therapeutics Holdings has a Z Score of 18.06. This is 167.56% higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The z score for all United States stocks is 107.11% lower than that of the firm.
Arcturus Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcturus Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcturus Therapeutics could also be used in its relative valuation, which is a method of valuing Arcturus Therapeutics by comparing valuation metrics of similar companies.Arcturus Therapeutics is currently under evaluation in z score category among related companies.
Arcturus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Arcturus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arcturus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcturus Therapeutics' value.Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 582 K | Geode Capital Management, Llc | 2023-12-31 | 538.3 K | Granahan Investment Management Inc.. | 2023-12-31 | 450.4 K | Jupiter Asset Management Limited | 2023-12-31 | 362.3 K | Point72 Asset Management, L.p. | 2023-09-30 | 335.3 K | Jpmorgan Chase & Co | 2023-12-31 | 322.8 K | Northern Trust Corp | 2023-12-31 | 247 K | Wayne Hummer Asset Mgmt Company | 2023-12-31 | 207.1 K | Nuveen Asset Management, Llc | 2023-12-31 | 194.7 K | Federated Hermes Inc | 2023-12-31 | 4.7 M | Blackrock Inc | 2023-12-31 | 2.4 M |
Arcturus Fundamentals
Return On Equity | -0.11 | ||||
Return On Asset | -0.11 | ||||
Profit Margin | (0.18) % | ||||
Operating Margin | (0.59) % | ||||
Current Valuation | 645.52 M | ||||
Shares Outstanding | 26.92 M | ||||
Shares Owned By Insiders | 8.81 % | ||||
Shares Owned By Institutions | 91.99 % | ||||
Number Of Shares Shorted | 4.21 M | ||||
Price To Earning | 119.50 X | ||||
Price To Book | 3.26 X | ||||
Price To Sales | 5.45 X | ||||
Revenue | 157.75 M | ||||
Gross Profit | 62.95 M | ||||
EBITDA | (1.2 M) | ||||
Net Income | (29.73 M) | ||||
Cash And Equivalents | 283.49 M | ||||
Cash Per Share | 10.67 X | ||||
Total Debt | 30.22 M | ||||
Debt To Equity | 0.58 % | ||||
Current Ratio | 3.14 X | ||||
Book Value Per Share | 10.38 X | ||||
Cash Flow From Operations | (18.1 M) | ||||
Short Ratio | 8.47 X | ||||
Earnings Per Share | (1.12) X | ||||
Target Price | 67.63 | ||||
Number Of Employees | 180 | ||||
Beta | 2.64 | ||||
Market Capitalization | 908.93 M | ||||
Total Asset | 429.4 M | ||||
Retained Earnings | (367.87 M) | ||||
Working Capital | 304.6 M | ||||
Current Asset | 54.55 M | ||||
Current Liabilities | 3.52 M | ||||
Z Score | 18.06 | ||||
Net Asset | 429.4 M |
About Arcturus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcturus Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcturus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcturus Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company was founded in 2013 and is headquartered in San Diego, California. Arcturus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.
Pair Trading with Arcturus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arcturus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcturus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Arcturus Stock
0.64 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
0.45 | MEIP | MEI Pharma Financial Report 9th of May 2024 | PairCorr |
0.41 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Arcturus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arcturus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arcturus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arcturus Therapeutics Holdings to buy it.
The correlation of Arcturus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arcturus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arcturus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arcturus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Arcturus Therapeutics Piotroski F Score and Arcturus Therapeutics Valuation analysis. Note that the Arcturus Therapeutics information on this page should be used as a complementary analysis to other Arcturus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Arcturus Stock analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Arcturus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 6.264 | Quarterly Revenue Growth (0.81) | Return On Assets (0.11) | Return On Equity (0.11) |
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.